肿瘤学与转化医学（英文）2026，Vol.12Issue(1)：15-37,23.DOI:10.1097/ot9.0000000000000120
Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials
Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials
Arpita Mukherjee1
作者信息
- 1. Shri Venkateshwara University,Gajraula,Uttar Prades,India
- 折叠
摘要
关键词
Glioblastoma/Immune checkpoint inhibitors/Tumor microenvironment/Programmed death-1/programmed death-ligand 1/Cytotoxic T-lymphocyte-associated antigen-4/Biomarkers/Combination therapy/Immunotherapy resistanceKey words
Glioblastoma/Immune checkpoint inhibitors/Tumor microenvironment/Programmed death-1/programmed death-ligand 1/Cytotoxic T-lymphocyte-associated antigen-4/Biomarkers/Combination therapy/Immunotherapy resistance引用本文复制引用
Arpita Mukherjee..Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials[J].肿瘤学与转化医学（英文）,2026,12(1):15-37,23.
